Bioprinting is the process of using cells and biological material (called bioinks) for 3D printing structures that allow living cells to multiply and grow. The technology can be applied across multiple uses, including organ replacement, cosmetic surgery, and drug development.
Advances in 3D printing technology have made bioprinting devices commercially viable. Bioprinting can be done using a range of methods, including magnetic levitation as well as inkjet-based, syringe-based, and laser-based printing. Going forward, its development will be focused on bioprinting devices and bioink materials, as having viable materials that can be safely implanted and used in the human body is key to the success of the industry. From a demand perspective, one of the primary drivers is the shrinking number of organ donors, along with population growth and the prevalence of chronic conditions that could be treated through organ and tissue replacement.
*Note: Currently, we do not actively cover this industry, but we have identified it as a potential industry to add to our coverage.
Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes.
No investor data is available